KNSAKiniksa Pharmaceuticals International, plc
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~12% a year FCF growth. The price demands less than its three-year revenue growth of 44% a year, expectations look modest.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What KNSA's price assumes
Kiniksa Pharmaceuticals International, plc trades at 78.3× earnings against 21.0× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.
Trailing P/E · Drug Manufacturers - Specialty & Generic median 21.0 · 3.73× the median: the market pays up for this one
- Price / sales
- 6.34
Price / sales · as of 2026-Q2
- Free cash flow yield
- 3.1%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- +12%
Growth the price implies · The price pays for +12% free cash flow growth a year for a decade; the business has delivered +63% a year over the last three.
Details›
- Price / bookas of 2026-Q2
- 8.15
- Healthcare median P/E503 names
- 27.9
- Drug Manufacturers - Specialty & Generic median P/E44 names
- 21.0
- Free cash flow, trailing twelve months
- $183M
- Market capitalisation78.0 million shares, counted Jul 24, 2026
- $5.98B
- 3-year revenue growth
- +44%
- 3-year free cash flow growth
- +63%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Drug Manufacturers, Specialty & Generic
Ranks #30 of 39 by RyuScore